Rehmann Capital Advisory Group Has $1.31 Million Stake in Bristol-Myers Squibb (NYSE:BMY)
Rehmann Capital Advisory Group Has $1.31 Million Stake in Bristol-Myers Squibb (NYSE:BMY)
Rehmann Capital Advisory Group trimmed its holdings in shares of Bristol-Myers Squibb (NYSE:BMY – Get Rating) by 2.0% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 17,069 shares of the biopharmaceutical company's stock after selling 341 shares during the quarter. Rehmann Capital Advisory Group's holdings in Bristol-Myers Squibb were worth $1,314,000 at the end of the most recent quarter.
根据美国证券交易委员会(美国证券交易委员会)的最新披露，雷曼资本咨询集团在第二季度减持了百时美施贵宝(纽约证券交易所代码：BMY-GET评级)的股票2.0%。该基金在本季度出售了341股后，持有这家生物制药公司的17,069股股票。截至最近一个季度末，Rehmann Capital Consulting Group持有的百时美施贵宝价值1,314,000美元。
Several other hedge funds have also recently bought and sold shares of BMY. Resonant Capital Advisors LLC grew its position in shares of Bristol-Myers Squibb by 0.3% in the second quarter. Resonant Capital Advisors LLC now owns 42,297 shares of the biopharmaceutical company's stock valued at $3,280,000 after purchasing an additional 134 shares during the last quarter. MV Capital Management Inc. grew its position in shares of Bristol-Myers Squibb by 10.7% in the first quarter. MV Capital Management Inc. now owns 1,391 shares of the biopharmaceutical company's stock valued at $102,000 after purchasing an additional 135 shares during the last quarter. Providence Wealth Advisors LLC grew its position in shares of Bristol-Myers Squibb by 0.5% in the first quarter. Providence Wealth Advisors LLC now owns 27,047 shares of the biopharmaceutical company's stock valued at $1,997,000 after purchasing an additional 139 shares during the last quarter. Rise Advisors LLC grew its position in shares of Bristol-Myers Squibb by 16.0% in the second quarter. Rise Advisors LLC now owns 1,007 shares of the biopharmaceutical company's stock valued at $78,000 after purchasing an additional 139 shares during the last quarter. Finally, Cornerstone Wealth Group LLC grew its position in Bristol-Myers Squibb by 4.9% during the second quarter. Cornerstone Wealth Group LLC now owns 2,982 shares of the biopharmaceutical company's stock worth $230,000 after buying an additional 140 shares in the last quarter. 76.54% of the stock is owned by institutional investors and hedge funds.
其他几家对冲基金最近也买卖了BMY的股票。Resonant Capital Advisors LLC第二季度将其在百时美施贵宝(Bristol-Myers Squibb)股票的持仓增加了0.3%。Resonant Capital Advisors LLC现在拥有这家生物制药公司42,297股股票，价值3,280,000美元，此前在上个季度又购买了134股。MV Capital Management Inc.在第一季度增持了百时美施贵宝股票10.7%。MV Capital Management Inc.现在持有这家生物制药公司1,391股股票，价值10.2万美元，该公司在上个季度又购买了135股。普罗维登斯财富顾问公司第一季度将其在百时美施贵宝股票的头寸增加了0.5%。普罗维登斯财富顾问有限责任公司现在拥有27,047股这家生物制药公司的股票，价值1,997,000美元，在上个季度又购买了139股。Rise Advisors LLC第二季度将其在百时美施贵宝(Bristol-Myers Squibb)股票的持仓增加了16.0%。Rise Advisors LLC现在拥有1007股这家生物制药公司的股票，价值7.8万美元，此前在上个季度又购买了139股。最后，Cornerstone Wealth Group LLC在第二季度将其在百时美施贵宝的头寸增加了4.9%。基石财富集团现在拥有2982股这家生物制药公司的股票，价值23万美元，在上个季度又购买了140股。76.54%的股票由机构投资者和对冲基金持有。
Bristol-Myers Squibb Stock Performance
百时美施贵宝股票表现
NYSE:BMY opened at $81.13 on Friday. Bristol-Myers Squibb has a 1 year low of $55.76 and a 1 year high of $81.43. The firm has a 50 day moving average of $74.98 and a 200-day moving average of $74.26. The company has a current ratio of 1.42, a quick ratio of 1.31 and a debt-to-equity ratio of 1.13. The stock has a market capitalization of $172.50 billion, a P/E ratio of 26.43, a price-to-earnings-growth ratio of 1.91 and a beta of 0.40.
纽约证券交易所：BMY周五开盘报81.13美元。百时美施贵宝的一年低点为55.76美元，一年高位为81.43美元。该公司的50日移动均线切入位在74.98美元，200日移动均线切入位在74.26美元。该公司的流动比率为1.42，速动比率为1.31，债务权益比率为1.13。该股市值为1,725亿美元，市盈率为26.43倍，市盈率为1.91倍，贝塔系数为0.40。
Bristol-Myers Squibb Dividend Announcement
百时美施贵宝宣布派息
The business also recently declared a quarterly dividend, which was paid on Tuesday, November 1st. Investors of record on Friday, October 7th were issued a $0.54 dividend. This represents a $2.16 dividend on an annualized basis and a dividend yield of 2.66%. The ex-dividend date was Thursday, October 6th. Bristol-Myers Squibb's dividend payout ratio is currently 70.36%.
该公司最近还宣布了季度股息，股息于11月1日(星期二)支付。记录在案的投资者在10月7日星期五获得了0.54美元的股息。这意味着年化股息为2.16美元，股息收益率为2.66%。除息日期为10月6日星期四。百时美施贵宝的派息比率目前为70.36%。
Insider Activity at Bristol-Myers Squibb
百时美施贵宝的内幕活动
In related news, EVP Ann Powell sold 25,000 shares of the firm's stock in a transaction that occurred on Wednesday, September 14th. The shares were sold at an average price of $70.75, for a total value of $1,768,750.00. Following the completion of the sale, the executive vice president now owns 50,476 shares of the company's stock, valued at $3,571,177. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Bristol-Myers Squibb news, EVP Ann Powell sold 25,000 shares of Bristol-Myers Squibb stock in a transaction on Wednesday, September 14th. The shares were sold at an average price of $70.75, for a total transaction of $1,768,750.00. Following the completion of the sale, the executive vice president now owns 50,476 shares of the company's stock, valued at approximately $3,571,177. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO David V. Elkins sold 133,951 shares of Bristol-Myers Squibb stock in a transaction on Tuesday, September 13th. The stock was sold at an average price of $71.30, for a total transaction of $9,550,706.30. Following the sale, the chief financial officer now directly owns 100,460 shares of the company's stock, valued at approximately $7,162,798. The disclosure for this sale can be found here. Insiders sold a total of 296,111 shares of company stock valued at $21,582,900 over the last quarter. Corporate insiders own 0.09% of the company's stock.
在相关新闻中，执行副总裁安·鲍威尔在9月14日星期三的一笔交易中出售了2.5万股该公司的股票。这些股票的平均价格为70.75美元，总价值为1,768,750.00美元。出售完成后，执行副总裁总裁现在持有该公司50,476股股票，价值3571,177美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可通过美国证券交易委员会网站。在其他百时美施贵宝的消息中，执行副总裁安·鲍威尔在9月14日星期三的一笔交易中出售了2.5万股百时美施贵宝股票。这些股票的平均价格为70.75美元，总成交额为1,768,750.00美元。出售完成后，执行副总裁总裁现在持有该公司50,476股股票，价值约3,571,177美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可通过此超链接。此外，首席财务官David·V·埃尔金斯在9月13日(星期二)的一次交易中出售了133,951股百时美施贵宝股票。该股以71.30美元的平均价格出售，总成交金额为9550,706.30美元。出售后，首席财务官现在直接拥有100,460股公司股票，价值约7,162,798美元。关于这次销售的披露可以找到这里。在上个季度，内部人士总共出售了296,111股公司股票，价值21,582,900美元。企业内部人士持有该公司0.09%的股票。
Wall Street Analysts Forecast Growth
华尔街分析师预测经济增长
BMY has been the topic of a number of recent research reports. BMO Capital Markets lifted their target price on Bristol-Myers Squibb from $92.00 to $94.00 and gave the stock an "outperform" rating in a research report on Monday, September 12th. Barclays cut their price target on shares of Bristol-Myers Squibb from $69.00 to $66.00 and set an "equal weight" rating for the company in a research note on Wednesday, October 12th. Credit Suisse Group began coverage on shares of Bristol-Myers Squibb in a research note on Thursday, November 17th. They set a "neutral" rating and a $78.00 price target for the company. StockNews.com began coverage on shares of Bristol-Myers Squibb in a research note on Wednesday, October 12th. They set a "strong-buy" rating for the company. Finally, Atlantic Securities raised their price target on shares of Bristol-Myers Squibb from $85.00 to $88.00 and gave the stock an "overweight" rating in a research note on Thursday, November 10th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Bristol-Myers Squibb currently has a consensus rating of "Moderate Buy" and an average price target of $79.00.
BMY一直是最近一些研究报告的主题。BMO Capital Markets在9月12日(周一)的一份研究报告中将百时美施贵宝的目标价从92.00美元上调至94.00美元，并给予该股“跑赢大盘”的评级。巴克莱在10月12日星期三的一份研究报告中将百时美施贵宝的股票目标价从69.00美元下调至66.00美元，并为该公司设定了“同等权重”评级。瑞士信贷集团在11月17日星期四的一份研究报告中开始报道百时美施贵宝的股票。他们为该公司设定了“中性”评级和78.00美元的目标价。StockNews.com在10月12日星期三的一份研究报告中开始报道百时美施贵宝的股票。他们为该公司设定了“强力买入”评级。最后，大西洋证券将百时美施贵宝股票的目标价从85.00美元上调至88.00美元，并在11月10日星期四的一份研究报告中给予该股“增持”评级。一名投资分析师对该股的评级为卖出，六名分析师给予持有评级，六名分析师给予买入评级，一名分析师对该股给予强力买入评级。根据MarketBeat的数据，百时美施贵宝目前的普遍评级为“中等买入”，平均目标价为79.00美元。
About Bristol-Myers Squibb
关于百时美施贵宝
(Get Rating)
(获取评级)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis.
百时美施贵宝公司在全球发现、开发、许可、制造和营销生物制药产品。它提供血液学、肿瘤学、心血管学、免疫学、纤维化、神经科学和新冠肺炎疾病的产品。该公司的产品包括治疗多发性骨髓瘤的口服免疫调节药物Revlimid；用于降低NVAF中风/系统性栓塞风险和治疗DVT/PE的口服抑制剂Eiquis；用于抗癌适应症的Opdivo；用于多发性骨髓瘤患者的Pomalyst/Imnovid；以及用于成人活动期RA和牛皮癣关节炎的Orencia。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Bristol-Myers Squibb (BMY)
- Why CSL Ltd Stock Could Be Worth a Look
- MarketBeat: Week in Review 11/28 – 12/02
- Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
- Institutions Are Buying Ambarella, Should You?
- Can ZIM Defy Broad Downturn In The Container Shipping Industry?
- 免费获取StockNews.com关于百时美施贵宝(BMY)的研究报告
- 为什么CSL有限公司的股票值得一看
- MarketBeat：回顾一周11/28-12/02
- Okta Inc.庆祝收益节节攀升，但他们能持续这种提振吗？
- 机构正在购买安巴雷拉，你应该吗？
- ZIM能否抵御集装箱航运业的普遍低迷？
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY – Get Rating).
想看看其他对冲基金持有哪些BMY吗？访问HoldingsChannel.com获取百时美施贵宝(纽约证券交易所代码：BMY-GET Rating)的最新13F备案文件和内幕交易信息。
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
接受百时美施贵宝日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收最新新闻和分析师对百时美施贵宝及相关公司评级的每日摘要。
译文内容由第三方软件翻译。